E x p l o r i n g
t h e
p o w e r
o f
n e u r o s c i e n c e
i g n i t i n g
t h e
p o s s i b i l i t i e s
o f
l i f e
Vision · Mission
L e a d i n g
i n n o v a t o r
i n
C N S
t r e a t m e n t
P i o n e e r i n g a f f o r d a b l e i n n o v a t i o n s t o p a t i e n t s
History
2020
• Ignis Therapeutics founded.
2021
• $185 million Series A financing, setting a new record for Series A investments in China's life sciences industry during that year.
• Acquisition of rights to 6 products from SK Biopharmaceuticals for Greater China region.
2022
• Acquisition of rights to Monarch eTNS system from NeuroSigma for Greater China region.
• Submission of NDA for Cenobamate in Hong Kong.
2023
• NDA approval of Cenobamate in Hong Kong.
• Initiation of Solriamfetol Phase 3 clinical trial in mainland China.
• Collaboration with Chinese Academy of Sciences on antidepressant drug development.
2024
• Inauguration of first manufacturing facility —— Ignis Suzhou plant.
• Research center founded.
• NDA approval of Solriamfetol in Hong Kong.
• Submission of NDA for Cenobamate in mainland China.
• Submission of NDA for Solriamfetol in mainland China.
2025
• Ignis Suzhou secures drug manufacturing license for Suzhou site.
• The clinical trial application for IGS01 has been accepted by the CDE.
• Cooperation agreement with the China Association Against Epilepsy (CAAE).
• 翼弗瑞® and 翼朗清® were officially approved in China.
• The Class 1 new drug IGS01 approved for clinical trials, intended for the treatment of Parkinson's disease.
"We anticipate collaborating with partners to unlock the full potential of innovations and jointly forge a blueprint for a vibrant, healthier future."
Address
46F, BM InterContinental Business Center, No.100 Yutong Road, Jing’an District, Shanghai, China
